ATE446759T1 - Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden - Google Patents

Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden

Info

Publication number
ATE446759T1
ATE446759T1 AT04764755T AT04764755T ATE446759T1 AT E446759 T1 ATE446759 T1 AT E446759T1 AT 04764755 T AT04764755 T AT 04764755T AT 04764755 T AT04764755 T AT 04764755T AT E446759 T1 ATE446759 T1 AT E446759T1
Authority
AT
Austria
Prior art keywords
patients suffering
oxcarbazepine
chronic pain
sleep
pain
Prior art date
Application number
AT04764755T
Other languages
English (en)
Inventor
Donald Manning
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0320637A external-priority patent/GB0320637D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE446759T1 publication Critical patent/ATE446759T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04764755T 2003-09-03 2004-09-02 Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden ATE446759T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0320637A GB0320637D0 (en) 2003-09-03 2003-09-03 Organic compounds
US53737804P 2004-01-16 2004-01-16
PCT/EP2004/009797 WO2005020968A2 (en) 2003-09-03 2004-09-02 Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Publications (1)

Publication Number Publication Date
ATE446759T1 true ATE446759T1 (de) 2009-11-15

Family

ID=34276821

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764755T ATE446759T1 (de) 2003-09-03 2004-09-02 Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden

Country Status (18)

Country Link
US (1) US20060270658A1 (de)
EP (1) EP1663247B1 (de)
JP (1) JP2007513056A (de)
KR (1) KR20060118426A (de)
AT (1) ATE446759T1 (de)
AU (1) AU2004268381B2 (de)
BR (1) BRPI0414112A (de)
CA (1) CA2537060A1 (de)
DE (1) DE602004023861D1 (de)
IL (1) IL173822A0 (de)
IS (1) IS8373A (de)
MA (1) MA28036A1 (de)
MX (1) MXPA06002392A (de)
NO (1) NO20061515L (de)
RU (1) RU2369393C2 (de)
SG (1) SG146631A1 (de)
TN (1) TNSN06072A1 (de)
WO (1) WO2005020968A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
DE602007012236D1 (de) * 2006-04-26 2011-03-10 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR102486435B1 (ko) 2022-04-25 2023-01-10 주식회사 제이비플랜트 산업용 냉동기기의 친환경 패널의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
EP1553934A1 (de) * 2002-10-17 2005-07-20 Novartis AG Pharmazeutische zusammensetzung zur behandlung von schmerzen mit oxicarbazepin, oder derivaten davon und cox2-hemmern

Also Published As

Publication number Publication date
WO2005020968A3 (en) 2005-05-19
AU2004268381B2 (en) 2009-06-18
TNSN06072A1 (en) 2007-10-03
JP2007513056A (ja) 2007-05-24
NO20061515L (no) 2006-06-06
KR20060118426A (ko) 2006-11-23
CA2537060A1 (en) 2005-03-10
MA28036A1 (fr) 2006-07-03
IL173822A0 (en) 2006-07-05
EP1663247A2 (de) 2006-06-07
MXPA06002392A (es) 2006-06-20
US20060270658A1 (en) 2006-11-30
WO2005020968A2 (en) 2005-03-10
RU2369393C2 (ru) 2009-10-10
SG146631A1 (en) 2008-10-30
RU2006110550A (ru) 2007-12-20
AU2004268381A1 (en) 2005-03-10
DE602004023861D1 (de) 2009-12-10
BRPI0414112A (pt) 2006-10-31
IS8373A (is) 2006-03-24
EP1663247B1 (de) 2009-10-28

Similar Documents

Publication Publication Date Title
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
SE0001899D0 (sv) New compounds
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
RU2008127882A (ru) Лечение пищевода барретта
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
MX2009011900A (es) Curacion de herida diabetica.
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
GB2446341A (en) Method and system for transdermal drug delivery
NO20053032L (no) Anvendelse av 2,5-dihydroxybenzensulfoniske forbindelser for behandling av lidelser basert pa en forstyrrelse av NO produksjon og/eller av regulering av EDHF funksjon.
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GEP201606538B (en) Preoperative treatment of post operative pain
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
TW200626133A (en) Oral medication for twice-daily administration
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
FR2853245B1 (fr) Utilisation du quinquina pour la preparation d'un medicament stimulant l'angiogenese
DE602006002126D1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties